No Data
HC Wainwright & Co. Reiterates Buy on Immix Biopharma, Maintains $7 Price Target
Express News | California Institute for Regenerative Medicine Awards Funding for CAR-T Nxc-201 U.S. Al Amyloidosis Clinical Trial (Nexicart-2)
H.C. Wainwright Maintains Immix Biopharma(IMMX.US) With Buy Rating, Maintains Target Price $7
Buy Rating Affirmed for Immix Biopharma Amid Promising NXC-201 Trial Outcomes and Market Potential
Express News | Immix Biopharma Inc - Data From Ex-US Clinical Trial Reported at Asgct 2024 Showed a 92% Overall Response Rate
Express News | Immix Biopharma Doses 1St Patient in U.S. Al Amyloidosis Trial With CAR-T Nxc-201